Vascular Biogenics Ltd (VBLT)

[gr8db8]

VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference

TEL AVIV, Israel, Sept. 17, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that complete Phase 2 data on VB-111 in combination with Bevacizumab (Avastin™) will be presented at the European Society for Medical Oncology's (ESMO) European Cancer Congress 2015, being held September 25th-29th in Vienna, Austria.

Presentation Details:
Date: Sunday, September 27th at 9:15am (CET)
Section: Proffered Paper Session: Central Nervous System, LEHAR 3
Title: Phase 2 study of VB-111, an anti-cancer gene therapy, as monotherapy followed by combination of VB-111 with bevacizumab, in patients with recurrent Glioblastoma
Presenter: Andrew J. Brenner, MD, PhD
Cancer Therapy and Research Center
University of Texas Health Science Center
Department of Medicine
San Antonio, Texas
Location: LEHAR 3

"We look forward to this opportunity at ECC 2015 to present complete results from this important Phase 2 trial of VB-111 in rGBM," stated Professor Dror Harats, CEO of VBL Therapeutics. "The presentation will include response rates in patients, as well as updated results on overall survival and response rate. We are excited to move forward with development of this first-in-class biologic agent and continue recruiting to our recently launched pivotal Phase 3 study in rGBM."